Success treating severe malaria in Nigeria
Abuja, Nigeria 15th June 2016 - “Mortality rates in those states where we ran our severe malaria project fell from 25 to just one percent. These results are, in part, due to the project and show that the use of injectable artesunate for severe malaria works.”
Dr Kolawole Maxwell, Malaria Consortium Country Director was speaking at an event in Abuja which featured the results of our Improved Severe Malaria Outcomes project across three states: Oyo, Enugu and Cross-River. “The use of injectable artesunate for severe malaria should be scaled up across all states in Nigeria as stakeholders work toward the achievement of national case management targets,” he added.
Malaria is a serious public health concern in Nigeria, accounting for 30 percent of all childhood deaths and 25 percent of deaths in children under one year of age. The entire Nigerian population is at risk of malaria all year round. Severe malaria is deadly and particularly dangerous for pregnant women and children. It represents the end-stage of untreated or improperly treated malaria, resulting in a near 100 percent mortality rate if left unaddressed.
Until fairly recently, quinine was the drug of choice for such cases. But with the release of the World Health Organization’s revised guidelines in 2010 came a new recommendation that artesunate, a derivative of artemisinin that is injected directly into the vein, replace quinine as the preferred treatment for severe malaria. In support of this policy change, Malaria Consortium’s UNITAID-funded project worked to reduce mortality from severe malaria through the accelerated global adoption of injectable artesunate.
Today, Malaria Consortium is holding an event to share results from the three-year project in Abuja, focusing on sharing results from Nigeria with key stakeholders, policymakers, clinicians, donors, researchers and implementers. It also provides an opportunity to discuss the current practices around the treatment of severe malaria and how these can be improved.
The project, Improving Severe Malaria Outcomes (ISMO), involved supply and demand management of injectable artesunate in six countries – Nigeria, Uganda, Kenya, Malawi, Cameroon and Ethiopia. Malaria Consortium led the project with our partner Medicines for Malaria Venture and in collaboration with the government as well as other partners to support the design, implementation and evaluation of activities in the three states. The project trained 24 master trainers and 440 facility-based mentors in 115 health facilities, as well as supplying 138,000 vials of the treatment.
The result was a sharp drop in the mortality rate due to severe malaria. In addition, the project successfully demonstrated that more effective management of severe malaria with user-friendly injectable artesunate is not only possible, but also accepted by service providers and stakeholders. With sufficient funding, this means that it could be scaled up across all states in Nigeria.
“The Nigerian government is pleased to see such impressive results from this project on severe malaria,” said, Dr Godwin Ntadom, who represented National Coordinator of the National Malaria Elimination Programme. “We remain committed to the fight against this deadly disease and the overarching goal of eliminating malaria from our country. Effective management of severe malaria is an essential step to help achieve this.”
The event was attended by the Commissioners and Permanent Secretary of Health Ministry of the three focal states, the Director of Public Health of the Federal Ministry of Health, community members, key stakeholders of the National Malaria Elimination Programme and the Roll Back Malaria Partnership.
About Malaria Consortium: Malaria Consortium works with partners, including all levels of government, to improve the lives of all, especially the poorest and marginalised, in Africa and Asia. We target key health burdens, including malaria, pneumonia, dengue and neglected tropical diseases, along with other factors that impact child and maternal health.